Area of research
Immunology · Oncology
Research interest
Research interests include CAR-T cell therapy research, Immune Cell Function and Interaction, Mesenchymal stem cell research, and SARS-CoV-2 and COVID-19 Research.
CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma
ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression
Clonal hematopoiesis landscape in frequent blood donors
Blood-based detection of MMP11 as a marker of prostate cancer progression regulated by the ALDH1A1-TGF-β1 signaling mechanism
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation
Blood-based detection of MMP11 as a marker of prostate cancer progression regulated by the ALDH1A1-TGF-β1 signaling mechanism
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma
Impedimetric Nanobiosensor for the Detection of SARS-CoV-2 Antigens and Antibodies
Ecological and clinical evidence of the establishment of West Nile virus in a large urban area in Europe, Berlin, Germany, 2021 to 2022
ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma
Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers
Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy
Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer
9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients
AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma
NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients
Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-disease
Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine
SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care
Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19
Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies
“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma
P06.12 Combination therapy of CAR-NK-cells and anti-PD-1 antibody results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity <i>in vivo</i>
P06.13 A novel local treatment approach? Targeted immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors through locally administered HER2-AAVs in combination with CAR-NK cells
CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
Low level of exosomal long non-coding RNA <i>HOTTIP</i> is a prognostic biomarker in colorectal cancer
Expression of Glypican 3 Is an Independent Prognostic Biomarker in Primary Gastro-Esophageal Adenocarcinoma and Corresponding Serum Exosomes
P12.04 Synergistic effects of combination therapy of CAR-NK cells and anti-PD-1 antibody result in high efficacy against advanced stage orthotopic glioblastoma grafts in a syngeneic mouse model and induce protective anti-tumor immunity in vivo